Stryker Neurovascular Trevo ProVue Retriever - HSA Registration DE0502244
Access comprehensive regulatory information for Stryker Neurovascular Trevo ProVue Retriever in the Singapore medical device market through Pure Global AI's free database. This CLASS D medical device is registered under HSA registration number DE0502244 and owned by Stryker Neurovascular. The device was registered on October 08, 2018.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.
It is indicated for use to restore blood flow in the neurovasculature by removing thrombus: - for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion (LVO), and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy should start within 6 hours of symptom onset. - for patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. - for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, LVO of the ICA or MCA-M1 segments with smaller core infarcts (0-50cc for age <80 years, 0-20cc for age ≥80 years). Endovascular therapy should start within 6-24 hours of time last seen well in patients who are ineligible for IV t-PA or who fail IV t-PA therapy.